Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Australian Bio-Investment Forum July 2007
21 slides from Optiscan Imaging's conference presentation, Jul 10, 2007
Slide 1: Australian Bio-Investment Forum July 2007
For personal use only Australian Bio-Investment Forum July 2007
Slide 2: Forward looking statements
For personal use only Forward looking statements This presentation contains "forward-looking" statements within the meaning of the United States’ Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, includi
Slide 3: Corporate Structure
Corporate Structure For personal use only • Ordinary shares on issue : 104 million • Market capitalisation 30 Jun 07: A$ 48 million • Cash at bank as at 31 Dec 06 : A$ 5.0 million • 2006/07 Product Sales A$ 5.49 million • Net Operating Cash Burn 06/07: A$ 0.3 million p.m.
Slide 4: Optiscan Overview
Optiscan Overview For personal use only • Developer and quality certified manufacturer of patented miniaturised laser scanning confocal microscopes for medical markets • Partnership strategy for large global high growth medical markets • US$1.2B pa flexible endoscope market - partner Pentax • US$1.0
Slide 5: An innovative endomicroscope platform uses patented fibre optic confocal technology
An innovative endomicroscope platform uses patented fibre optic confocal technology For personal use only • Optiscan’s technology provides in vivo Laser Detector digital histology – live, real time cellular images during procedures: Control • Microscopic sub-cellular view System ~1,000x magnificatio
Slide 6: Endomicroscope imaging provides virtual biopsies of tissue from inside the patient
Endomicroscope imaging provides virtual biopsies of tissue from inside the patient For personal use only Images courtesy of Professor Adrian Polglase, Cabrini Hospital, Australia
Slide 7: Exceptional efficacy has been demonstrated in extensive clinical trials
Exceptional efficacy has been demonstrated in extensive clinical trials For personal use only Study Focus Sensitivity Specificity Accuracy Neoplasia in ulcerative colitis 94.7% 98.3% 97.8% Diagnosis of Barrett‘s esophagus 98.8% 94.4% 97.5% Neoplasia in Barrett’s esophagus 91.7% 99.0% 97.5% Neoplasia
Slide 8: Optiscan's endomicroscopes offer clinicians several key advantages
Optiscan’s endomicroscopes offer clinicians several key advantages For personal use only • Leverages proven histopathology principles of disease diagnosis • Easily learned by clinicians • Key advantages: 9 real time information 9 non invasive (without biopsy) 9 at low-cost • Clinical application are
Slide 9: Optiscan Product Portfolio and Pipeline
Optiscan Product Portfolio and Pipeline For personal use only Research Clinical Regulatory Product Product Use Launch Sales & Dev Trials Clearance -ion Pentax GI non- 9FDA invasive ISC 1000 diagnosis 9CE Mark Optiscan Preclinical FIVE 1 research 9 Rigid Endo- Intra – Pilot microscopes operative tria
Slide 10: Carl Zeiss rigid endo-microscope deal
Carl Zeiss rigid endo-microscope deal For personal use only • Optiscan’s first agreement for rigid endo-microscopes • Carl Zeiss becomes exclusive partner in one segment of rigid endo- microscopes • Deal financials • $4M in milestone payments over 3 years • Anticipated $16M in product sales over fir
Slide 11: Carl Zeiss group information
Carl Zeiss group information For personal use only • World renowned market leaders in optical and opto-electrical instruments • Autonomous businesses generally ranked first or second in their markets • Core global markets include medical and biomedical research • Excellent track record of driving sa
Slide 12: Further commercialisation of rigid endo-microscopes
Further commercialisation of rigid endo-microscopes For personal use only • Many attractive market segments remain open for further commercialisation of rigid-endomicroscopes • General Surgery • Urology • Gynaecology/Women’s Health • Abdominal and thoracic robotic surgery • Orthopaedics • Dermatolog
Slide 13: Pentax ISC 1000 partnered for flexible endoscopes
partnered for flexible endoscopes For personal use only Pentax ISC 1000 System • Flexible endoscope market, value ~US$1.2B • Pentax global share 15-20% • Optiscan miniaturised confocal scanner integrated into Pentax flexible endoscope • Optiscan • Pentax • ISC 1000 sales launch in March 2006 • Optis
Slide 14: $7M Development Agreement
$7M Development Agreement For personal use only • A$4.8M of expenditure to accelerate market penetration • Target obtaining additional reimbursement for flexible endo- microscope procedures in Europe and USA • CRO controlled multi-centre studies in Europe and USA • Leveraging excellent single centre
Slide 15: Optiscan FIVE1 is a pre-clinical instrument
is a pre-clinical instrument For personal use only • Innovative in-vivo research instrument enabling new research • Target markets in drug development and translational research • Full Optiscan production and direct sales • Second endomicroscope product from the one platform • High margin capture •
Slide 16: Optiscan Financial Results
Optiscan Financial Results For personal use only FY05/06 FY1H06/07 • Product sale revenues A$ 3.23M A$ 2.48M • Total revenues A$ 5.63M A$ 5.45M • Operating expenses A$ 7.00M A$ 3.49M • R&D expense percentage 45% 48% • Net profit (loss) after tax A$ (3.94M) A$ 0.10M • Cash A$ 6.65M A$ 4.96M • Other A
Slide 17: Revenue from design and development is a new element in Optiscan's business
Revenue from design and development is a new element in Optiscan’s business For personal use only • A strong product development pipeline important for Optiscan partners • Commitment to building continued market leadership through ongoing design and development • Pentax to pay $2.2M to partially fun
Slide 18: Continued modest sales growth is required to become profitable
Continued modest sales growth is required to become profitable For personal use only • First half profit of $0.1M included once off back royalty payments of A$2.1M • Progress over the last 4 months has added three new revenue streams to the business for 2007/08 • Carl Zeiss rigid endo-microscope dea
Slide 19: Optiscan has a commercially experienced Board and management team
Optiscan has a commercially experienced Board and management team For personal use only Grant Latta, Chairman : Former MD Pacific Dunlop Foods and Foam&Fibre 2002 Director BTA, Sunrice; Aust Comp Tribunal Matthew Barnett, CEO : Experienced GM with strong commercialisation 2002 focus; Amcor, Boston C
Slide 20: Optiscan Summary
Optiscan Summary For personal use only • Commercialisation of unique endomicroscope technology underway • Pentax partnership flexible endo-microscopes • Carl Zeiss partnership for segment of rigid endo-microscopes • Optiscan FIVE1 pre-clinical endo-microscopes • Market penetration to accelerate with
Slide 21: The global leader in microscopic imaging technologies for medical markets
For personal use only The global leader in microscopic imaging technologies for medical markets
Optiscan Imaging — Australian Bio-Investment Forum July 2007 on 6ix